Literature DB >> 24844467

Non-AIDS-Defining Malignancies in the HIV-Infected Population.

Chia-Ching J Wang1, Michael J Silverberg, Donald I Abrams.   

Abstract

With the advent of effective combination antiretroviral therapy, HIV infection has been transformed from a fatal disease to a chronic condition. There is renewed clinical interest in long-term morbidities, including malignancies that occur disproportionately within this population. Non-AIDS-defining cancers (NADCs) are a significant source of morbidity and mortality in the aging HIV-infected population. There are data to suggest that incidence rates are elevated among HIV-infected individuals for many cancer sites, particularly those with a confirmed or suspected infectious etiology. The complex interplay between behavioral risk factors, coexistence of viral infections, immunodeficiency and antiretroviral therapy makes it difficult to analyze why certain cancers develop more frequently in HIV-infected individuals. The challenge to clinicians caring for HIV-infected patients is to develop and implement effective means to screen, treat, and prevent NADCs in the future. This review presents data on whether NADCs are increased in the HIV-Infected population, as well as ongoing research on epidemiology, prevention and pathogenesis of this evolving aspect of the HIV epidemic.

Entities:  

Year:  2014        PMID: 24844467      PMCID: PMC4085772          DOI: 10.1007/s11908-014-0406-0

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  73 in total

1.  High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma.

Authors:  A van den Berg; L Visser; S Poppema
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

Review 2.  Hodgkin's disease: biology and origin of Hodgkin and Reed-Sternberg cells.

Authors:  H S Stein; M Hummel
Journal:  Cancer Treat Rev       Date:  1999-06       Impact factor: 12.111

3.  Elevated risk of lung cancer among people with AIDS.

Authors:  Anil K Chaturvedi; Ruth M Pfeiffer; Leonard Chang; James J Goedert; Robert J Biggar; Eric A Engels
Journal:  AIDS       Date:  2007-01-11       Impact factor: 4.177

Review 4.  The role of cytokines in classical Hodgkin lymphoma.

Authors:  Brian F Skinnider; Tak W Mak
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

Review 5.  Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.

Authors:  Aimee R Kreimer; Gary M Clifford; Peter Boyle; Silvia Franceschi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-02       Impact factor: 4.254

6.  Trends in cancer risk among people with AIDS in the United States 1980-2002.

Authors:  Eric A Engels; Ruth M Pfeiffer; James J Goedert; Phillip Virgo; Timothy S McNeel; Steven M Scoppa; Robert J Biggar
Journal:  AIDS       Date:  2006-08-01       Impact factor: 4.177

Review 7.  Human papillomavirus and anal neoplasia.

Authors:  Joel Palefsky
Journal:  Curr HIV/AIDS Rep       Date:  2008-05       Impact factor: 5.071

8.  Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma.

Authors:  Gary M Clifford; Martin Rickenbach; Jerry Polesel; Luigino Dal Maso; Ingrid Steffen; Bruno Ledergerber; Andri Rauch; Nicole M Probst-Hensch; Christine Bouchardy; Fabio Levi; Silvia Franceschi
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177

Review 9.  Immune escape mechanisms in Hodgkin's disease.

Authors:  S Poppema; M Potters; L Visser; A M van den Berg
Journal:  Ann Oncol       Date:  1998       Impact factor: 32.976

10.  Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.

Authors:  Andreas Rosenwald; George Wright; Karen Leroy; Xin Yu; Philippe Gaulard; Randy D Gascoyne; Wing C Chan; Tong Zhao; Corinne Haioun; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Elias Campo; Emili Montserrat; Armando Lopez-Guillermo; German Ott; H Konrad Muller-Hermelink; Joseph M Connors; Rita Braziel; Thomas M Grogan; Richard I Fisher; Thomas P Miller; Michael LeBlanc; Michael Chiorazzi; Hong Zhao; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Louis M Staudt
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307

View more
  19 in total

1.  Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A meta-analysis.

Authors:  Jessica R Allegretti; Edward L Barnes; Anna Cameron
Journal:  Inflamm Bowel Dis       Date:  2015-05       Impact factor: 5.325

2.  Understanding Community-based HIV/AIDS Service Organizations: An Invaluable Source of HPV-related Cancer Information for At-risk Populations.

Authors:  Lisa T Wigfall; Patricia Goodson; George B Cunningham; Idethia S Harvey; Tamika D Gilreath; Maurice Adair; Bambi W Gaddist; Carmen Hampton Julious; Daniela B Friedman
Journal:  J Health Commun       Date:  2020-01-08

3.  T-Cell Immune Dysregulation and Mortality in Women With Human Immunodeficiency Virus.

Authors:  Brandilyn A Peters; Jee-Young Moon; David B Hanna; Olaf Kutsch; Margaret Fischl; Caitlin A Moran; Adaora A Adimora; Stephen Gange; Nadia R Roan; Katherine G Michel; Michael Augenbraun; Anjali Sharma; Alan Landay; Seema Desai; Robert C Kaplan
Journal:  J Infect Dis       Date:  2022-02-15       Impact factor: 7.759

Review 4.  Promise and Challenges of Checkpoint Inhibitor Therapy for Progressive Multifocal Leukoencephalopathy in HIV.

Authors:  Sydney Corey; Bryan R Smith; Irene C M Cortese
Journal:  Curr HIV/AIDS Rep       Date:  2022-10-01       Impact factor: 5.495

Review 5.  ImPlementation REsearCh to DEvelop Interventions for People Living with HIV (the PRECluDE consortium): Combatting chronic disease comorbidities in HIV populations through implementation research.

Authors:  Joyonna Carrie Gamble-George; Christopher T Longenecker; Allison R Webel; David H Au; Arleen F Brown; Hayden Bosworth; Kristina Crothers; William E Cunningham; Kevin A Fiscella; Alison B Hamilton; Christian D Helfrich; Joseph A Ladapo; Amneris Luque; Jonathan N Tobin; Gail E Wyatt
Journal:  Prog Cardiovasc Dis       Date:  2020-03-19       Impact factor: 8.194

6.  Malignancies diagnosed before and after anal squamous cell carcinomas: A SEER registry analysis.

Authors:  Krupa S Jani; Shou-En Lu; James D Murphy; Paul B Romesser; Krishan R Jethwa; Diana Li; Anupama Chundury; Abraham J Wu; Lara Hathout; Christopher L Hallemeier; Salma K Jabbour
Journal:  Cancer Med       Date:  2021-05-07       Impact factor: 4.452

7.  Yield of yearly routine physical examination in HIV-1 infected patients is limited: A retrospective cohort study in the Netherlands.

Authors:  Marleen A van Amsterdam; Sander van Assen; Herman G Sprenger; Kasper R Wilting; Ymkje Stienstra; Wouter F W Bierman
Journal:  PLoS One       Date:  2017-06-21       Impact factor: 3.240

Review 8.  The Role of Transforming Growth Factor Beta-1 in the Progression of HIV/AIDS and Development of Non-AIDS-Defining Fibrotic Disorders.

Authors:  Annette J Theron; Ronald Anderson; Theresa M Rossouw; Helen C Steel
Journal:  Front Immunol       Date:  2017-11-02       Impact factor: 7.561

Review 9.  The Double-Edged Sword Role of Viruses in Gastric Cancer.

Authors:  Paulina Niedźwiedzka-Rystwej; Ewelina Grywalska; Rafał Hrynkiewicz; Mikołaj Wołącewicz; Rafał Becht; Jacek Roliński
Journal:  Cancers (Basel)       Date:  2020-06-24       Impact factor: 6.639

10.  B-cell clonogenic activity of HIV-1 p17 variants is driven by PAR1-mediated EGF transactivation.

Authors:  Cinzia Giagulli; Francesca Caccuri; Simone Zorzan; Antonella Bugatti; Alberto Zani; Federica Filippini; Ekta Manocha; Pasqualina D'Ursi; Alessandro Orro; Riccardo Dolcetti; Arnaldo Caruso
Journal:  Cancer Gene Ther       Date:  2020-10-22       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.